Table 5 Prescription of combination therapy for comorbidities
Antihypertensives | Total | Without comorbidities | Comorbidities3 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Diabetes mellitus | Renal insufficiency | Hypercholesterolaemia | CHD | Post myocardial infarction | Heart failure | Stroke | Obesity | Asthma/COPD | |||
[N (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | |
2-drug combinations | 1613 (100) | 186 (100) | 215 (100) | 86 (100) | 358 (100) | 247 (100) | 36 (100) | 30 (100) | 139 (100) | 218 (100) | 98 (100) |
Diuretic plus | |||||||||||
Beta-blocker | |||||||||||
Fixed-dose coformulation | 103 (6.4) | 17 (9.2) | 11 (5.1) | 2 (2.3) | 33 (9.2) | 14 (5.7) | - | 1 (3.3) | 4 (2.9) | 20 (9.2) | 1 (1.0) |
Monopreparation | 106 (6.6) | 14 (7.5) | 12 (5.6) | 5 (5.8) | 20 (5.6) | 15 (6.1) | 2 (5.6) | - | 9 (6.5) | 16 (7.3) | 13 (13.3) |
CCB1 | |||||||||||
Fixed-dose coformulation | 2 (0.1) | - | - | - | - | 1 (0.4) | - | - | 1 (0.6) | - | - |
Monopreparation | 58 (3.6) | 7 (3.8) | 2 (0.9) | 6 (7.0) | 8 (2.2) | 9 (3.6) | 2 (5.6) | 3 (10.0) | 5 (3.2) | 6 (2.8) | 10 (10.2) |
ACE inhibitor | |||||||||||
Fixed-dose coformulation | 372 (23.1) | 43 (23.1) | 54 (25.1) | 28 (32.6) | 75 (20.9) | 52 (21.1) | 5 (13.9) | 16 (53.3) | 36 (26.1) | 50 (22.9) | 13 (13.3) |
Monopreparation | 132 (8.2) | 4 (2.2) | 15 (7.0) | 7 (8.1) | 24 (6.7) | 26 (10.5) | 5 (13.9) | 2 (6.7) | 11 (8.0) | 21 (9.6) | 17 (17.3) |
Angiotensin II antagonist | |||||||||||
Fixed-dose coformulation | 396 (24.6) | 52 (28.0) | 61 (28.4) | 15 (17.4) | 91 (25.4) | 49 (19.8) | 4 (11.1) | 5 (16.7) | 31 (22.5) | 59 (27.1) | 29 (29.6) |
Monopreparation | 23 (1.4) | 2 (1.1) | 2 (0.9) | 2 (2.3) | 7 (2.0) | 4 (1.6) | - | 1 (3.3) | 3 (2.2) | 1 (0.5) | 1 (1.0) |
CCB plus | |||||||||||
Beta-blocker | |||||||||||
Fixed-dose coformulation | - | - | - | - | - | - | - | - | - | - | - |
Monopreparation | 77 (4.8) | 15 (8.1) | 12 (5.6) | 5 (5.8) | 11 (3.1) | 11 (4.5) | 4 (11.1) | - | 8 (5.8) | 7 (3.2) | 4 (4.1) |
ACE inhibitor | |||||||||||
Fixed-dose coformulation | 1 (0.1) | 1 (0.5) | - | - | - | - | - | - | - | - | - |
Monopreparation | 65 (4.0) | 7 (3.8) | 8 (3.7) | 6 (7.0) | 13 (3.6) | 13 (5.3) | 3 (8.3) | - | 4 (2.9) | 4 (1.8) | 7 (7.1) |
Angiotensin II antagonist | |||||||||||
Fixed-dose coformulation | - | - | - | - | - | - | - | - | - | - | - |
Monopreparation | 35 (2.2) | 7 (3.8) | 2 (0.9) | - | 8 (2.2) | 6 (2.4) | 1 (2.8) | - | 5 (3.6) | 5 (2.3) | 1 (1.0) |
Beta-blocker plus | |||||||||||
other antihypertensive | |||||||||||
Fixed-dose coformulation | 9 (0.6) | 1 (0.5) | - | - | 4 (1.1) | 1 (0.4) | - | 1 (3.3) | 2 (1.3) | - | - |
Monopreparation | 172 (10.7) | 13 (7.0) | 26 (12.1) | 4 (4.7) | 47 (13.1) | 37 (14.9) | 10 (27.8) | 1 (3.3) | 13 (9.4) | 19 (8.7) | 2 (2.0) |
Other | 62 (3.8) | 3 (1.6) | 10 (4.7) | 6 (7.0) | 17 (4.7) | 9 (3.6) | - | - | 7 (5.1) | 10 (4.6) | - |
3-drug combinations | 222 (100) | 15 (100) | 42 (100) | 17 (100) | 52 (100) | 32 (100) | 2 (100) | 1 (100) | 15 (100) | 25 (100) | 21 (100) |
Diuretic plus ACE inhibitor plus CCB | |||||||||||
Monopreparation | |||||||||||
8 (3.6) | - | 1 (2.4) | 1 (5.9) | 2 (3.8) | 2 (6.3) | - | - | - | - | 2 (9.5) | |
Diuretic plus beta-blocker plus 2 | |||||||||||
Monopreparation | |||||||||||
120 (54.1) | 6 (40.0) | 26 (61.9) | 5 (29.4) | 26 (50.0) | 19 (59.4) | 1 (50.0) | - | 9 (60.0) | 17 (68.0) | 11 (52.4) | |
Diuretic plus antiadrenergic agent plus2 | |||||||||||
Monopreparation | |||||||||||
10 (4.5) | 2 (13.3) | - | 2 (11.8) | 3 (5.8) | 1 (3.1) | - | - | - | - | 2 (9.5) | |
Other | 84 (37.8) | 7 (46.7) | 15 (35.7) | 9 (52.9) | 21 (40.4) | 10 (31.3) | 1 (50.0) | 1 (100) | 6 (40.0) | 8 (32.0) | 6 (28.6) |